Action & Accountability

As a company focused on improving the health of patients everywhere, impact has always been central to Teva. This comes to life through our Environmental, Social and Governance (ESG) strategy, which guides us in minimizing our impact on the planet, advancing health and equity and dedicating ourselves to quality, ethics and transparency.

In 2021, we took action by advancing our ESG efforts and strengthening the connection between ESG and our business—holding ourselves accountable to future progress.

Discover more

Teva’s ESG Progress Highlights 2021 

Toggle

Integrating ESG further into our business

  • 13 targets established in key areas, including access to medicines, ethics, scope 3 GHG emissions and responsible supply chain
  • $5 billion sustainability-linked bond issued, tying ESG targets to financing strategy
  • Executive compensation tied to progress toward ESG targets
Read more

Making our medicines more accessible, affordable and available

  • 4 global access to medicines programs launched to-date (50% of our 2025 target), 2 in low- and middle-income countries (LMICs)
  • 585 marketing authorizations approved in LMICs to help make medicines more accessible for those who need them
  • $487 million worth of medicines donated to patients in need
Read more

Limiting our impact on the environment

  • 13% reduction of scope 1 and 2 GHG emissions (vs. 2019)
  • 8% reduction in waste from operations and water use in areas where demand for water may soon exceed supply (vs. 2020)
  • 100% of sites handling drug products assessed for antimicrobial discharge
  • 4% increase in energy from renewable sources to 33% total (vs. 2020)
Read more

Respecting and empowering our people

  • 1.8% increase in women in executive and senior management positions (vs. 2020)
  • Nearly 90% of employees trained on “Fostering an Inclusive Culture”
  • 80%+ of our employees believe:
    • They can be themselves at work
    • Our culture promotes inclusion and diversity
    • Everyone is treated fairly, regardless of personal background
Read more

Conducting our business ethically and transparently

  • 3 new position statements published on risk management, patient safety and responsible supply chain
  • Top 1% in our industry in the EcoVadis sustainable procurement assessment, showing how we keep ESG central in decisions about supply chain partners
  • 20,000+ employees (99.6% of those assigned) trained on ethics
Read more

Uncover more in our 2021 ESG Progress Report

NPS-ALL-NP-00571 MAY 2022